Skip to content
Medical Health Aged Care

Medisca Secures Settlement With FlackTek, Reinforcing Patent Strength of MAZ® Mixer

Medisca 2 mins read
PLATTSBURGH, N.Y.--BUSINESS WIRE--

Medisca and FlackTek have reached a settlement to resolve their patent dispute relating to the Medisca MAZ® mixer and related mixing technologies set forth in Medisca U.S. patent numbers 10,420,705, 10,765,600, 11,090,224, 11,096,864, 10,231,903, and 10,993,876.

The confidential settlement resolves the pending litigation. “This settlement validates the investment Medisca has made over the past decade in the MAZ innovation and technology,” said Sanjay Goorachurn, CEO of Medisca Pharmaceutique Inc. “We will continue to invest in more innovative products and solutions to meet our customers’ evolving needs globally and ensure that new and existing customers receive the high-quality products they deserve."

Medisca remains committed to protecting its intellectual property rights and proprietary technologies. Medisca has ongoing litigations against Fagron B.V., HiperScan GmbH, and Gako Deutschland GmbH for infringement of Medisca German counterpart patents. Those suits were filed in the Munich district court of Germany and request injunctions and monetary remedies.

About Medisca

Medisca is a global corporation with locations throughout North America, Australia, and Europe, that contributes to healthcare by leveraging strong partnerships that deliver customized solutions with an unwavering commitment to quality and innovation. Backed by 30+ years and a strong foundation in pharmaceutical compounding supply, Medisca is a business-to-business company that delivers comprehensive offerings by providing value, consistency, responsiveness, and loyalty.

The Medisca MAZ® mixer provides an efficient, uniform, and high-quality solution for compounding hundreds of formulations and is protected by a robust portfolio of patents across the globe. As Partners in Wellness, Medisca offers an unfailing devotion to improving lives across a multitude of needs and people. For more information, visit www.medisca.com and follow us on LinkedIn, Facebook, and YouTube.


Contact details:

Medisca Communications
[email protected]
1-800-665-6334

Media

More from this category

  • General News, Medical Health Aged Care
  • 12/03/2026
  • 14:07
Parliament of Australia

Public hearing concerning the National Redress Scheme

TheJoint Standing Committee on Implementation of the National Redress Schemewill hold a public hearing in Canberra on Friday, 13 March 2026, for itsinquiry into the continuing operation of the Scheme. Committee Chair, Ms Jodie Belyea MP, said the Committee is grateful for the contributions made in support of the inquiry to date. ‘The National Redress Scheme plays a central role in Australia’s response to institutional child sexual abuse. It is an important program for a significant number of people. The Committee has received a substantial number of submissions in support of our current inquiry, and public hearings over the coming…

  • Energy, Medical Health Aged Care
  • 12/03/2026
  • 12:11
Sweltering Cities

The cost of keeping cool is making Australians sick: New report reveals millions forced to ration cooling during record heat

12 March 2026 Sweltering Cities has today released the findings of its 2026 Summer Survey, exposing a national health crisis driven by the rising cost of keeping cool. With data from more than 2,600 respondents across 766 postcodes, the report proves that for many Australians the high cost of staying cool is having serious physical and mental health impacts. The 2025/26 summer saw 68% of all respondents report feeling unwell due to heat. However, the survey reveals that this burden is falling most heavily on those already struggling with the cost of living. For renters and people with disabilities, the…

  • Medical Health Aged Care
  • 12/03/2026
  • 10:01
Monash University

Monash Researchers Awarded up to $22.4 Million AUD to Develop New Medicines for Restoring Lymphatic Pumping

Monash University is partnering with the University of Missouri and the University of Pennsylvania to develop first-in-class medicines designed to reverse poor lymphatic vessel contraction and transport function, backed by an up to $22.4 million AUD Award from the Advanced Research Projects Agency for Health (ARPA-H). The researchers join ARPA-H’s GLIDE (Groundbreaking Lymphatic Interventions and Drug Exploration) program to transform how both primary lymphatic diseases and common chronic diseases are treated by developing innovative therapeutics that alleviate, repair or regenerate a dysfunctional lymphatic vascular system. Professor Arthur Christopoulos, Dean of the Faculty of Pharmacy and Pharmaceutical Sciences, said the work…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.